Javier Corral Selected Research

Lenalidomide (CC 5013)

9/2019	Incorporating Bortezomib in the Management of Plasmablastic Lymphoma.
1/2018	Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Javier Corral Research Topics

Disease

28	Thrombosis (Thrombus) 09/2023 - 08/2002
21	Venous Thrombosis (Deep-Vein Thrombosis) 11/2021 - 08/2002
13	Thrombophilia 03/2023 - 05/2008
13	Myocardial Infarction 09/2010 - 08/2002
9	Venous Thromboembolism 09/2023 - 05/2008
9	Hemorrhage 10/2021 - 01/2003
7	Inflammation (Inflammations) 01/2021 - 09/2004
6	Neoplasms (Cancer) 01/2021 - 01/2011
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2013 - 07/2003
5	Atrial Fibrillation 10/2021 - 09/2004
5	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 01/2020 - 10/2013
3	Inborn Genetic Diseases (Disease, Hereditary) 11/2023 - 01/2018
3	Congenital Disorders of Glycosylation 01/2022 - 11/2019
3	Stroke (Strokes) 08/2012 - 09/2006
3	Ischemic Stroke 08/2012 - 09/2006
2	Rare Diseases (Rare Disease) 05/2024 - 10/2020
2	COVID-19 01/2021 - 01/2021
2	Vascular Diseases (Vascular Disease) 01/2021 - 08/2012
2	Triple Negative Breast Neoplasms 12/2020 - 07/2019
2	Pulmonary Embolism 12/2019 - 06/2010
2	Protein S Deficiency (Deficiency, Protein S) 01/2017 - 04/2007
2	Neoplasm Metastasis (Metastasis) 01/2016 - 01/2016
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2014 - 07/2006
2	Necrosis 01/2013 - 02/2008
2	Cardiotoxicity 01/2013 - 02/2012
2	Peripheral Arterial Disease 08/2012 - 08/2006
2	Atherosclerosis 08/2012 - 09/2004
2	Sepsis (Septicemia) 01/2011 - 04/2005
2	Hyperlipidemias (Hyperlipidemia) 09/2007 - 08/2006
1	Retinitis Pigmentosa (Pigmentary Retinopathy) 05/2024
1	Anastomotic Leak 12/2023
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 11/2023
1	Drug-Related Side Effects and Adverse Reactions 01/2023
1	Hematologic Diseases (Blood Diseases) 01/2023
1	Primary Myelofibrosis (Myelosclerosis) 09/2022
1	Cytopenia 09/2022
1	Disease Susceptibility (Diathesis) 01/2021
1	Angioedema 10/2020
1	Hereditary Angioedemas 01/2020
1	Thromboembolism 12/2019
1	Bacterial Infections (Bacterial Infection) 12/2019

Drug/Important Bio-Agent (IBA)

42	AntithrombinsIBA 09/2023 - 11/2003
13	AnticoagulantsIBA 01/2023 - 04/2007
9	Hemostatics (Antihemorrhagics)IBA 10/2020 - 03/2005
9	SerpinsIBA 01/2016 - 01/2004
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2006
6	Factor XIII (Coagulation Factor XIII)IBA 09/2010 - 08/2002
5	Protein CIBA 12/2019 - 04/2007
4	Thrombin FDA Link 09/2023 - 03/2009
4	Factor XII (Hageman Factor)IBA 10/2020 - 12/2005
3	FibrinIBA 09/2023 - 04/2005
3	Glycoproteins (Glycoprotein)IBA 01/2022 - 07/2003
3	phosphomannomutaseIBA 01/2022 - 01/2019
3	Heparin (Liquaemin)FDA LinkGeneric 01/2021 - 01/2016
3	Fibrinogen (Factor I)FDA Link 01/2021 - 09/2004
3	Congenital disorder of glycosylation type 1AIBA 10/2020 - 10/2013
3	factor V LeidenIBA 11/2010 - 05/2008
3	Protease Inhibitors (Protease Inhibitor)IBA 04/2007 - 05/2005
3	plasma protein Z (protein Z)IBA 04/2007 - 05/2005
2	Retroelements (Retrotransposon)IBA 05/2024 - 08/2022
2	Factor XI (Plasma Thromboplastin Antecedent)IBA 10/2021 - 11/2019
2	Polysaccharides (Glycans)IBA 01/2020 - 01/2017
2	Blood Coagulation Factors (Coagulation Factor)IBA 11/2019 - 01/2017
2	Lenalidomide (CC 5013)FDA Link 09/2019 - 01/2018
2	Bortezomib (Velcade)FDA Link 09/2019 - 03/2008
2	MicroRNAs (MicroRNA)IBA 01/2017 - 03/2011
2	Thromboplastin (Tissue Factor)IBA 01/2016 - 09/2004
2	Factor VIII (Coagulation Factor VIII)IBA 09/2013 - 01/2013
2	AnthracyclinesIBA 01/2013 - 02/2012
2	LipidsIBA 08/2010 - 08/2006
2	antithrombin Cambridge IIIBA 03/2009 - 05/2007
2	Prothrombin (Factor II)IBA 05/2008 - 08/2002
2	N- (oxo- 5,6- dihydrophenanthridin- 2- yl)- N,N- dimethylacetamide hydrochlorideIBA 02/2008 - 04/2005
2	Integrin alpha2IBA 01/2008 - 07/2003
2	Asparaginase (Elspar)FDA Link 09/2007 - 07/2006
2	Annexin A5IBA 12/2002 - 09/2002
1	Biocompatible Materials (Biomaterials)IBA 12/2023
1	TESIBA 11/2023
1	Antiphospholipid AntibodiesIBA 11/2023
1	eculizumab FDA Link 01/2023
1	Intravenous Immunoglobulins (IVIG)FDA Link 09/2022
1	SteroidsIBA 09/2022
1	ParaffinIBA 01/2021
1	Dacarbazine (DIC)FDA LinkGeneric 01/2021
1	fibrin fragment D (D-dimer)IBA 01/2021
1	Cyclooxygenase 1IBA 01/2021
1	Formaldehyde (Formol)FDA Link 01/2021
1	von Willebrand FactorIBA 01/2021
1	atezolizumabIBA 12/2020
1	130-nm albumin-bound paclitaxelIBA 12/2020
1	ElementsIBA 10/2020
1	Estrogens (Estrogen)FDA Link 01/2020
1	Oral ContraceptivesIBA 12/2019
1	Protein Isoforms (Isoforms)IBA 12/2019

Therapy/Procedure

8	Therapeutics 10/2021 - 10/2005
4	Thrombolytic Therapy 09/2010 - 08/2002
2	Ligation 03/2023 - 04/2005
2	Drug Therapy (Chemotherapy) 01/2021 - 12/2020
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2023
1	Immunotherapy 12/2020